These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 3125920)

  • 1. Guidelines on postmarketing surveillance. Joint committee of ABPI, BMA, CSM, and RCGP.
    Joint committee of ABPI, BMA, CSM, and RCGP
    Br Med J (Clin Res Ed); 1988 Feb; 296(6619):399-400. PubMed ID: 3125920
    [No Abstract]   [Full Text] [Related]  

  • 2. Concerns with postmarketing surveillance.
    Norvell MJ; Anderson RJ
    Am J Hosp Pharm; 1984 Jan; 41(1):54, 56. PubMed ID: 6695933
    [No Abstract]   [Full Text] [Related]  

  • 3. Data quality in post-marketing surveillance.
    Girard M
    Adverse Drug React Acute Poisoning Rev; 1986; 5(2):87-95. PubMed ID: 3529880
    [No Abstract]   [Full Text] [Related]  

  • 4. Manufacturer-hospital collaboration to improve patient care quality.
    DeGasparis P; Magill KA; Milone T
    Hosp Top; 1983; 61(4):15-6. PubMed ID: 10260122
    [No Abstract]   [Full Text] [Related]  

  • 5. [Quality control: observation record on the use of pliable bags].
    Avenard G; Cavalier J; Couquelet M
    Rev Fr Transfus Immunohematol; 1985 Feb; 28(1):45-9. PubMed ID: 3992127
    [No Abstract]   [Full Text] [Related]  

  • 6. Record linkage studies for postmarketing drug surveillance: data quality and validity considerations.
    Stergachis AS
    Drug Intell Clin Pharm; 1988 Feb; 22(2):157-61. PubMed ID: 3349931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Policy issues concerning antimicrobials: problems with the regulatory process governing their introduction.
    Simon HJ
    Hosp Formul; 1985 May; 20(5):629-31, 634. PubMed ID: 10271104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse drug event reporting. Improving the low US reporting rates.
    Edlavitch SA
    Arch Intern Med; 1988 Jul; 148(7):1499-503. PubMed ID: 3382293
    [No Abstract]   [Full Text] [Related]  

  • 9. A primer on postmarketing surveillance.
    Drug Inf J; 1987; 21(1):67-107. PubMed ID: 10281639
    [No Abstract]   [Full Text] [Related]  

  • 10. Guidelines for company-sponsored Safety Assessment of Marketed Medicines (SAMM) guidelines. Medicines Control Agency, Committee on Safety of Medicines, Royal College of General Practitioners, British Medical Association and Association of the British Pharmaceutical Industry (November 1993).
    Br J Clin Pharmacol; 1994 Aug; 38(2):95-7. PubMed ID: 7981019
    [No Abstract]   [Full Text] [Related]  

  • 11. Promotion of medicines.
    Massam D
    Lancet; 1989 Jun; 1(8650):1330. PubMed ID: 2566856
    [No Abstract]   [Full Text] [Related]  

  • 12. Post-marketing surveillance of new drugs.
    Buckley EG
    J R Coll Gen Pract; 1987 Aug; 37(301):337-8. PubMed ID: 3448222
    [No Abstract]   [Full Text] [Related]  

  • 13. Not enough warning. GAO report finds FDA's medical device monitoring lacking.
    Hensley S
    Mod Healthc; 1997 Mar; 27(10):102, 104. PubMed ID: 10165267
    [No Abstract]   [Full Text] [Related]  

  • 14. Postmarketing surveillance study of a non-chlorofluorocarbon inhaler Postmarketing surveillance studies remain unethical.
    Patterson C
    BMJ; 1999 Mar; 318(7186):810-11. PubMed ID: 10215393
    [No Abstract]   [Full Text] [Related]  

  • 15. Why do doctors not report adverse drug reactions?
    Leiper JM; Lawson DH
    Neth J Med; 1985; 28(12):546-50. PubMed ID: 3911083
    [No Abstract]   [Full Text] [Related]  

  • 16. Demography of the UK adverse reactions register of spontaneous reports.
    Speirs CJ; Griffin JP; Weber JC; Glen-Bott M
    Health Trends; 1984 Aug; 16(3):49-52. PubMed ID: 10317533
    [No Abstract]   [Full Text] [Related]  

  • 17. New horizons in post-marketing surveillance.
    Waller P; Wood S
    Health Trends; 1993; 25(3):83. PubMed ID: 10131867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From the SNM Committee on Pharmacopeia: Exemption of radiopharmaceuticals from <797>.
    Hung JC;
    J Nucl Med; 2004 Oct; 45(10):13N, 16N. PubMed ID: 15551509
    [No Abstract]   [Full Text] [Related]  

  • 19. Secrecy and product liability litigation.
    Brahams D
    Lancet; 1990 Sep; 336(8717):737-8. PubMed ID: 1975905
    [No Abstract]   [Full Text] [Related]  

  • 20. Monitoring of drugs after marketing.
    J R Coll Gen Pract; 1983 Jul; 33(252):438-41. PubMed ID: 6887114
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.